Friday 23 October | |
Essentra PLC | Third Quarter Results |
Barclays PLC | Third Quarter Results |
London Stock Exchange Group PLC | Third Quarter Results |
InterContinental Hotels Group PLC | Third Quarter Results |
Airtel Africa PLC | Half Year Results |
Avation PLC | Full Year Results |
Monday 26 October | |
THG Holdings PLC | Third Quarter Results |
Tuesday 27 October | |
Bloomsbury Publishing PLC | Half Year Results |
Plus500 Ltd | Third Quarter Results |
St James's Place PLC | Third Quarter Results |
HSBC Holdings PLC | Third Quarter Results (at 0400 GMT) |
Dechra Pharmaceuticals PLC | Trading Statement |
Whitbread PLC | Half Year Results |
Shoe Zone PLC | Trading Statement |
BP PLC | Third Quarter Results |
Hunting PLC | Trading Statement |
First Derivatives PLC | Half Year Results |
Renalytix AI PLC | Full Year Results |
ContourGlobal Group PLC | Trading Statement |
Wednesday 28 October | |
John Laing Group PLC | Trading Statement |
Ibstock PLC | Trading Statement |
Gem Diamonds Ltd | Trading Statement |
Elementis PLC | Trading Statement |
International Biotechnology Trust PLC | Full Year Results |
GlaxoSmithKline PLC | Third Quarter Results (at midday) |
Next PLC | Trading Statement |
Bank of Ireland Group PLC | Trading Statement |
Omega Diagnostics Group PLC | Trading Statement |
Itaconix PLC | Half Year Results |
Thursday 29 October | |
Royal Dutch Shell PLC | Third Quarter Results |
Angle PLC | Half Year Results |
Standard Chartered PLC | Third Quarter Results (at 0415 GMT) |
WPP PLC | Trading Statement |
Helios Towers PLC | Third Quarter Results |
Smith & Nephew PLC | Trading Statement |
Lloyds Banking Group PLC | Third Quarter Results |
Travis Perkins PLC | Trading Statement |
KAZ Minerals PLC | Third Quarter Production |
BT Group PLC | Half Year Results |
International Personal Finance PLC | Trading Statement |
Indivior PLC | Third Quarter Results |
Glanbia plc | Third Quarter Results |
Foxtons Group PLC | Trading Statement |
Evraz PLC | Trading Statement |
Smith & Nephew PLC | Third Quarter Trading Statement |
Proactis Holdings PLC | Full Year Results |
Hilton Food Group PLC | Trading Statement |
Verona Pharma PLC | Third Quarter Results |
Copyright 2020 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Angle's Parsortix performs well on prostate cancer patients
Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.
Read more